Dalane Kitzman to Randomized Controlled Trials as Topic
This is a "connection" page, showing publications Dalane Kitzman has written about Randomized Controlled Trials as Topic.
Connection Strength
2.137
-
Upadhya B, Brubaker PH, Morgan TM, Eggebeen JD, Jao GT, Stewart KP, Kitzman DW. The effect of Aliskiren on exercise capacity in older patients with heart failure and preserved ejection fraction: A randomized, placebo-controlled, double-blind trial. Am Heart J. 2018 07; 201:164-167.
Score: 0.463
-
Upadhya B, Brubaker PH, Nicklas BJ, Houston DK, Haykowsky MJ, Kitzman DW. Long-term Changes in Body Composition and Exercise Capacity Following Calorie Restriction and Exercise Training in Older Patients with Obesity and Heart Failure With Preserved Ejection Fraction. J Card Fail. 2025 Mar; 31(3):497-507.
Score: 0.179
-
Kitzman DW, Lewis GD, Pandey A, Borlaug BA, Sauer AJ, Litwin SE, Sharma K, Jorkasky DK, Khan S, Shah SJ. A novel controlled metabolic accelerator for the treatment of obesity-related heart failure with preserved ejection fraction: Rationale and design of the Phase 2a HuMAIN trial. Eur J Heart Fail. 2024 Sep; 26(9):2013-2024.
Score: 0.178
-
Brubaker PH, Nelson WB, Kitzman DW. Response by Brubaker et al to Letter Regarding "A Randomized, Controlled Trial of Resistance Training Added to Caloric Restriction Plus Aerobic Exercise Training in Obese Heart Failure With Preserved Ejection Fraction". Circ Heart Fail. 2023 May; 16(5):e010419.
Score: 0.164
-
Pajewski NM, Berlowitz DR, Bress AP, Callahan KE, Cheung AK, Fine LJ, Gaussoin SA, Johnson KC, King J, Kitzman DW, Kostis JB, Lerner AJ, Lewis CE, Oparil S, Rahman M, Reboussin DM, Rocco MV, Snyder JK, Still C, Supiano MA, Wadley VG, Whelton PK, Wright JT, Williamson JD. Intensive vs Standard Blood Pressure Control in Adults 80?Years or Older: A Secondary Analysis of the Systolic Blood Pressure Intervention Trial. J Am Geriatr Soc. 2020 03; 68(3):496-504.
Score: 0.130
-
Upadhya B, Stacey RB, Kitzman DW. Preventing Heart Failure by Treating Systolic Hypertension: What Does the SPRINT Add? Curr Hypertens Rep. 2019 01 18; 21(1):9.
Score: 0.122
-
Kritchevsky SB, Beavers KM, Miller ME, Shea MK, Houston DK, Kitzman DW, Nicklas BJ. Intentional weight loss and all-cause mortality: a meta-analysis of randomized clinical trials. PLoS One. 2015; 10(3):e0121993.
Score: 0.094
-
Pandey A, Parashar A, Kumbhani D, Agarwal S, Garg J, Kitzman D, Levine B, Drazner M, Berry J. Exercise training in patients with heart failure and preserved ejection fraction: meta-analysis of randomized control trials. Circ Heart Fail. 2015 Jan; 8(1):33-40.
Score: 0.092
-
Haykowsky MJ, Kitzman DW. Exercise physiology in heart failure and preserved ejection fraction. Heart Fail Clin. 2014 Jul; 10(3):445-52.
Score: 0.089
-
Scott JM, Haykowsky MJ, Eggebeen J, Morgan TM, Brubaker PH, Kitzman DW. Reliability of peak exercise testing in patients with heart failure with preserved ejection fraction. Am J Cardiol. 2012 Dec 15; 110(12):1809-13.
Score: 0.079
-
Haykowsky M, Brubaker P, Kitzman D. Role of physical training in heart failure with preserved ejection fraction. Curr Heart Fail Rep. 2012 Jun; 9(2):101-6.
Score: 0.077
-
Whellan DJ, Ellis SJ, Kraus WE, Hawthorne K, Piña IL, Keteyian SJ, Kitzman DW, Cooper L, Lee K, O'Connor CM. Method for establishing authorship in a multicenter clinical trial. Ann Intern Med. 2009 Sep 15; 151(6):414-20.
Score: 0.064
-
Pastva AM, Reeves GR, Whellan DJ, Mentz RJ, Chen H, Bertoni AG, Duncan PW, Espeland MA, Reed SD, Nelson MB, O'Connor CM, Kitzman DW. Physical rehabilitation for older patients with acute HFpEF (REHAB-HFpEF) trial: Design and rationale. Am Heart J. 2026 Jul; 297:107420.
Score: 0.050
-
Leifer ES, Flynn KE, Keteyian SJ, Kitzman DW, Sachdev V. Supervised Exercise Training Improves Quality of Life in Chronic Heart Failure With Preserved Ejection Fraction: A META-ANALYSIS OF RANDOMIZED TRIALS. J Cardiopulm Rehabil Prev. 2025 Sep 01; 45(5):364-370.
Score: 0.048
-
Selvaraj S, Patel S, Sauer AJ, McGarrah RW, Jones P, Kwee LC, Windsor SL, Ilkayeva O, Muehlbauer MJ, Newgard CB, Borlaug BA, Kitzman DW, Shah SJ, Margulies KB, Husain M, Inzucchi SE, McGuire DK, Lanfear DE, Javaheri A, Umpierrez G, Mentz RJ, Sharma K, Kosiborod MN, Shah SH. Metabolic Effects of the SGLT2 Inhibitor Dapagliflozin in Heart Failure Across the Spectrum of Ejection Fraction. Circ Heart Fail. 2024 Nov; 17(11):e011980.
Score: 0.046
-
McMurray JJV, Docherty KF, de Boer RA, Hammarstedt A, Kitzman DW, Kosiborod MN, Maria Langkilde A, Reicher B, Senni M, Shah SJ, Wilderäng U, Verma S, Solomon SD. Effect of Dapagliflozin Versus Placebo on Symptoms and 6-Minute Walk Distance in Patients With Heart Failure: The DETERMINE Randomized Clinical Trials. Circulation. 2024 Mar 12; 149(11):825-838.
Score: 0.043
-
Kosiborod MN, Abildstrøm SZ, Borlaug BA, Butler J, Christensen L, Davies M, Hovingh KG, Kitzman DW, Lindegaard ML, Møller DV, Shah SJ, Treppendahl MB, Verma S, Petrie MC. Design and Baseline Characteristics of STEP-HFpEF Program Evaluating Semaglutide in Patients With Obesity HFpEF Phenotype. JACC Heart Fail. 2023 Aug; 11(8 Pt 1):1000-1010.
Score: 0.041
-
Gupta K, Spertus JA, Birmingham M, Gosch KL, Husain M, Kitzman DW, Pitt B, Shah SJ, Januzzi JL, Lingvay I, Butler J, Kosiborod M, Lanfear DE. Racial Differences in Quality of Life in Patients With Heart Failure Treated With Sodium-Glucose Cotransporter 2 Inhibitors: A Patient-Level Meta-Analysis of the CHIEF-HF, DEFINE-HF, and PRESERVED-HF Trials. Circulation. 2023 Jul 18; 148(3):220-228.
Score: 0.041
-
Beavers KM, Neiberg RH, Kritchevsky SB, Nicklas BJ, Kitzman DW, Messier SP, Rejeski WJ, Ard JD, Beavers DP. Association of Sex or Race With the Effect of Weight Loss on Physical Function: A Secondary Analysis of 8 Randomized Clinical Trials. JAMA Netw Open. 2020 08 03; 3(8):e2014631.
Score: 0.034
-
Houston DK, Miller ME, Kitzman DW, Rejeski WJ, Messier SP, Lyles MF, Kritchevsky SB, Nicklas BJ. Long-Term Effects of Randomization to a Weight Loss Intervention in Older Adults: A Pilot Study. J Nutr Gerontol Geriatr. 2019 Jan-Mar; 38(1):83-99.
Score: 0.031
-
Heerspink HJL, Andress DL, Bakris G, Brennan JJ, Correa-Rotter R, Dey J, Hou FF, Kitzman DW, Kohan D, Makino H, McMurray J, Perkovic V, Tobe S, Wigderson M, Parving HH, de Zeeuw D. Rationale and protocol of the Study Of diabetic Nephropathy with AtRasentan (SONAR) trial: A clinical trial design novel to diabetic nephropathy. Diabetes Obes Metab. 2018 06; 20(6):1369-1376.
Score: 0.029
-
Sharma A, Stevens SR, Lucas J, Fiuzat M, Adams KF, Whellan DJ, Donahue MP, Kitzman DW, Piña IL, Zannad F, Kraus WE, O'Connor CM, Felker GM. Utility of Growth Differentiation Factor-15, A Marker of Oxidative Stress and Inflammation, in Chronic Heart Failure: Insights From the HF-ACTION Study. JACC Heart Fail. 2017 10; 5(10):724-734.
Score: 0.028
-
Forman DE, Clare R, Kitzman DW, Ellis SJ, Fleg JL, Chiara T, Fletcher G, Kraus WE. Relationship of age and exercise performance in patients with heart failure: the HF-ACTION study. Am Heart J. 2009 Oct; 158(4 Suppl):S6-S15.
Score: 0.016